JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology therapy, demonstrated a median overall survival of 23 months ...

A Phase III randomized trial published in JAMA Network Open found no significant difference in symptom improvement between ...

At the risk of stating the obvious, when evaluating a new EDC, step one is ensuring the EDC is in fact better. EDC technology ...